Objective: Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication-defective herpes simplex virus (HSV)-based vectors can reduce pain-related behavior in animal models of pain. This clinical trial was carried out to assess the safety and explore the potential efficacy of this approach in humans. Methods: We conducted a multicenter, dose-escalation, phase I clinical trial of NP2, a replication-defective HSVbased vector expressing human preproenkephalin (PENK) in subjects with intractable focal pain caused by cancer. NP2 was injected intradermally into the dermatome(s) corresponding to the radicular distribution of pain. The primary outcome was safety. As secondary measures, efficacy of pain relief was assessed using a numeric rating scale (NRS), the Short Form McGill Pain Questionnaire (SF-MPQ), and concurrent opiate usage. Results: Ten subjects with moderate to severe intractable pain despite treatment with >200mg/day of morphine (or equivalent) were enrolled into the study. Treatment was well tolerated with no study agent-related serious adverse events observed at any point in the study. Subjects receiving the low dose of NP2 reported no substantive change in pain. Subjects in the middle-and high-dose cohorts reported pain relief as assessed by NRS and SF-MPQ. Interpretation: Treatment of intractable pain with NP2 was well tolerated. There were no placebo controls in this relatively small study, but the dose-responsive analgesic effects suggest that NP2 may be effective in reducing pain and warrants further clinical investigation. ANN NEUROL 2011;70:207-212 A significant limitation to the development of analgesic drugs is that off-target effects at doses below the maximal analgesic threshold restrict the ability to selectively interrupt nociceptive neurotransmission.
A significant limitation to the development of analgesic drugs is that off-target effects at doses below the maximal analgesic threshold restrict the ability to selectively interrupt nociceptive neurotransmission. 1 To address this limitation, we developed a series of replication-defective herpes simplex virus (HSV)-based vectors to deliver gene expression cassettes directly to dorsal root ganglion (DRG) neurons from skin inoculation. 2, 3 The anatomically defined projection of DRG axons allows targeting of specific ganglia by injection into selected dermatomes. In preclinical studies, the release of antinociceptive peptides or inhibitory neurotransmitters in spinal dorsal horn from the central terminals of transduced DRG neurons effectively reduced pain-related behaviors in rodent models of inflammatory pain, neuropathic pain, and pain caused by cancer. [4] [5] [6] [7] [8] [9] The human PENK gene encodes for preproenkephalin, a precursor protein proteolytically cleaved to produce the endogenous opioid peptides met-and leu-enkephalin. In the spinal cord, enkephalin peptides inhibit pain signaling through actions at presynaptic opioid receptors located on central terminals of primary afferent nociceptors and postsynaptic opioid receptors on second order neurons involved in nociceptive neurotransmission. 10 HSV vectors expressing opioid peptides appear to be particularly effective in animal models of inflammatory and cancer pain. 4, 5, 8 Because there have been no previous clinical trials of replication-defective HSV as a gene transfer vector, we undertook this phase I dose-escalation study of NP2, a PENK-expressing HSV vector, to assess the safety of the HSV-based gene transfer platform. As secondary outcome measures we evaluated the effect of vector-mediated delivery of PENK on pain, and on concurrent use of opiate medication.
Patients and Methods

Study Design
The study was sponsored and implemented by Diamyd Incorporated, a subsidiary of Diamyd Medical AB. The protocol was reviewed by the National Institutes of Health Recombinant DNA Advisory Committee, conducted in accordance with the US Food and Drug Administration-approved (investigational new drug #13613) in compliance with Good Clinical Practice and listed on ClinicalTrials.gov as ''Gene transfer for intractable pain: a phase I clinical trial to determine the maximum tolerable dose of a replication-defective herpes simplex virus type I (HSV-1) vector expressing human preproenkephalin (NP2) in patients with malignancies'' (#NCT00804076).
Manufacturing and Preclinical Evaluation
NP2 is a replication-defective HSV-based vector deleted for the essential immediate early (IE) genes ICP4 and ICP27 with a human cytomegalovirus IE promoter-driven human PENK gene expression cassette inserted into both ICP4 loci. The deletions of the ICP4 loci also remove the promoters for the ICP22 and ICP47 genes, rendering NP2 defective in expression of 4 HSV IE genes.
NP2 was propagated in an ICP4 and ICP27 complementing cell line created by sequentially transfecting Vero cells (American Type Culture Collection Catalogue #CCL-81) with separate plasmids containing ICP4 and ICP27 and drug selection markers. Clonally derived cell lines were tested for complementing activity and stability prior to subsequent retransfection and drug selection. The final isolated cell line, PHC11-54-1, provided stable propagation and amplification of NP2 and was expanded as a master cell bank (MCB). The certified MCB was employed to produce the NP2 master virus bank (MVB) and subsequently to produce the NP2 clinical product in compliance with FDA current Good Manufacturing Practices (cGMP). The MCB, MVB, and clinical cGMP products each passed a thorough panel of safety and identity testing criteria. A Good Laboratory Practice (GLP) preclinical toxicology program was implemented in mice for up to 90 days after inoculation. No target organ of toxicity was identified at any time point. A comprehensive GLP preclinical biodistribution study established that quantifiable vector genomes were limited to the site of injection and the innervating DRG.
The NP2 clinical cGMP stock was produced by infecting 10-layer cell factories of MCB cells with NP2 MVB. The infected culture was harvested, salt treated, and clarified by centrifugation and filtration. Residual DNA was digested with endonuclease, and the vector was purified by ion exchange chromatography. The product was further purified and concentrated by tangential-flow filtration, and recovered NP2 was sterile filtered, formulated, filled into cryovials, and stored below À70 C until use. The final product was tested for safety (including absence of replication competent vector), identity, purity, titer, and enkephalin expression. A stability program was initiated to monitor NP2 product titer, enkephalin expression, pH, appearance, and sterility over the course of the trial.
Subjects
Subjects 18 years of age or older with intractable pain due to primary or metastatic cancer that was moderate to severe in intensity (!40 on a 100mm visual analogue scale) despite (1) stable analgesic treatment with at least 200mg/day morphine or equivalent or (2) having reached a stable maximum tolerated dose of narcotic or other analgesics that was <200mg/day morphine or equivalent were eligible for enrollment. Trial subjects were excluded if they were pregnant and had to be able to reliably provide pain assessment. Subjects with a clinical diagnosis of active herpetic disease within 6 months of recruitment or vaccination to prevent HSV infection were excluded. We also excluded patients with recent chemotherapy, radiation therapy, or a surgical stabilization procedure. Subjects with serious uncontrolled medical conditions other than malignancy, positive serology for human immunodeficiency virus, hepatitis B or hepatitis C, severe anemia, uncontrolled coagulopathy or bleeding diathesis, or documented immunodeficiency were excluded.
This phase I study was approved by the institutional review boards of the University of Michigan and Chesapeake Research Review and was conducted in accordance with the principles of the Declaration of Helsinki. All subjects executed written informed consent prior to screening. Subjects that passed all inclusion and exclusion screening criteria had vector administered as 10 intradermal injections of approximately 100ll each (total 1.0ml) distributed within the dermatome(s) corresponding to the radicular distribution of the pain in a single session on study day 0. Enrollment of the first cohort commenced with a dose of 1 Â 10 7 plaque forming units (pfu).
Subjects were monitored for 4 weeks, and dosing was sequentially escalated to the 1 Â 10 8 and 1 Â 10 9 pfu cohorts following approval by the Data and Safety Monitoring Committee (DSMC).
Study Assessments
Subjects were observed for at least 12 hours after dosing before being discharged and were scheduled for re-examination at 1, 3, 7, 10, 14, 21, and 28 days postdosing and monthly thereafter. Safety data examination included adverse events, a full physical examination, vital signs, mucositis evaluation, and clinical laboratory analyses. Secondary measures included the numeric rating scale (NRS) for pain intensity and the Short Form McGill Pain Questionnaire (SF-MPQ) completed by the subject on study day 0 prior to dosing and on postdosing days 1, 3, 7, 10, 14, 21, and 28. An SF12 short form Health Survey and complete Eastern Cooperative Oncology Group performance status were similarly completed on study day 0 and day 28. Concurrent opiate analgesic usage was recorded on postdosing study days 1, 3, 7, 10, 14, 21, and 28.
Results
Subjects
Ten subjects were enrolled into the study. Four subjects received 1 Â 10 7 pfu NP2, 3 subjects received 1 Â 10 8 pfu NP2, and 3 subjects received 1 Â 10 9 pfu NP2.
Subject demographics are presented in Table 1 . The mean predosing NRS pain score was 8.0 6 0.6 for subjects in Cohort 1, 9.0 6 0.57 for subjects in Cohort 2, and 7.7 6 1.3 for subjects in Cohort 3.
Adverse Events
No treatment-related serious adverse events (SAEs) were reported during the 4-month follow-up period. Of the 10 terminal cancer subjects enrolled, 8 completed the 28-day study, and 4 subjects completed the 4-month follow-up. Four of the 6 discontinued subjects were withdrawn due to death (2 at the low dose, 1 at the mid dose, and 1 in the high-dose cohort); 1 subject requested discontinuation after 105 days of follow-up, and 1 subject discontinued for reasons that were not established. Six of the 10 enrolled subjects reported a total of 8 SAEs. These adverse events included progression of malignancy, obstruction of the common bile duct, pneumonia, asthma, and pleuritic pain. None of the SAEs were judged to be related to the investigational product by the study site principal investigator or the DSMC. Nine of the 10 enrolled subjects had 1 or more treatment-emergent adverse event (TEAE) during the 4 months following drug delivery. A total of 72 TEAEs were reported. The TEAEs that were deemed as possibly related to treatment were all mild in severity and resolved, including transient injection site erythema and pruritus, and 1 subject who had a transient elevation in body temperature.
No subject seroconverted from anti-HSV antibody (Ab) negative at baseline to Ab positive at 1 or 4 months after inoculation with NP2, and none of the subjects who were anti-HSV Ab positive at enrollment showed any increase in anti-HSV Ab titer after receiving NP2. No HSV DNA was detected by quantitative polymerase chain reaction (PCR) in the blood or urine of subjects at 1, 7, or 14 days following NP2 dosing.
Secondary Outcomes
The principal secondary outcome of this trial was the NRS of pain. Because of the terminal nature of subjects with cancer, by 2 months postdosing there was only 1 patient surviving in the 10 7 pfu cohort, and 2 each in the 10 8 pfu NP2 cohort showed a similar reduction in average NRS pain scores to approximately 50% of baseline at day 1 that continued to decline to approximately 20% of baseline values by day 7; average NRS pain score remained below this level through the 28-day time point (Fig, A) . Although this was not a blinded study, and there were no placebo controls, there was an apparent dose-response that could be measured as the percentage maximal possible effect on the average NRS score from days 7 through 28 (see Fig, B) . A similar trend was observed in section I of the subject-reported SF-MPQ scores (Table 2) , representing the sum of 15 individual scores (each between 0 and 3) in response to questions about pain (sensory and affective). The dose of concurrent opiate medication that patients continued to take under the direction of their treating physician ranged broadly, and it is difficult to draw conclusions on this parameter given the small number of patients in each cohort (Table 3) . 
Discussion
Despite extensive basic research and clinical trials, chronic pain is a condition that often remains refractory to available treatments. [11] [12] [13] Innovative approaches have largely focused on the search for novel targets for analgesic drugs, based on insights gained from broad-based investigations into the neurobiology of chronic pain. 14 Unfortunately, it has been difficult to identify amenable targets for systemically delivered small molecules that are located exclusively within nociceptive pathways. Not unlike more conventional analgesic agents, 15, 16 even drugs designed to interact with newly identified apparently nociceptive-specific targets such as the vanilloid receptor TRPV1 have been found to have biological roles unrelated to nociception that pose a significant constraint to their use. 17, 18 HSV is a ubiquitous, naturally neurotropic virus spread by contact of skin or mucous membranes that establishes a persistent latent state in neurons of sensory ganglia. By the same cellular transduction mechanisms, replication-defective HSV-based vectors delivered subcutaneously or intradermally transfer genetic material into DRG neurons in vivo. 19 The human PENK gene carried by NP2 encodes preproenkephalin, a precursor protein that is processed to produce 6 met-enkephalin and 1 leuenkephalin moieties; endogenous opioid peptides that are the naturally occurring high-affinity ligands of the delta opioid receptor. 10 In this clinical trial, the mechanism of action of the vector was not directly confirmed, but in animal studies the analgesic effects achieved by HSVmediated expression of PENK are blocked by opioid receptor antagonists naloxone and intrathecal naltrexone, [4] [5] [6] suggesting a site of action at spinal opioid receptors, and in vitro biological effects of vector-produced enkephalins are blocked by 10pM naltrindole, 20 consistent with in vitro activity at the delta opioid receptor. Although met-enkephalin has a higher affinity for the delta compared to the mu opioid receptor, 21 it is certainly possible that the analgesic effects observed are mediated through mu as well as delta opioid receptors. Conceptually, HSV-mediated delivery of PENK represents a logical extension of the technique of 4 peripheral nerve damage, 6 and bone cancer.
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Because this was the first human trial employing HSV vectors to achieve gene transfer, we elected to carry out the phase I clinical trial for safety and dose finding in patients with pain caused by cancer. The safety profile observed in this study was not unanticipated. Oncolytic recombinant HSV-1 viruses without transgenes that are intended to kill malignant cells by limited replication have been injected directly into tumors in brain, liver, and skin in >200 subjects to date with no reported test agent-related SAEs. [29] [30] [31] [32] [33] Replication-competent HSV recombinants have also been examined in clinical trials as potential vaccines against genital herpes. Although these approaches have in some cases generated quite high anti-HSV antibody levels (without effectively preventing HSV infection), no drugrelated SAEs have been observed. [34] [35] [36] This phase I clinical trial primarily addressed the question of whether intradermal delivery of NP2 to skin would prove to be safe and well tolerated by subjects. The small number of patients and the absence of placebo controls warrant circumspect interpretation of the secondary outcome measures. But the observation that subjects in the low-dose cohort had little change in the NRS or SF-MPQ whereas subjects in the higher-dose cohorts reported substantial reduction in NRS and improvement in SF-MPQ is encouraging. Based partially upon these results, Diamyd has initiated a randomized, double-blind placebo-control phase II clinical trial in a similar patient population (''A phase II, randomized, double blind, placebo-controlled, multicenter study to investigate the impact of NP2 in subjects with intractable pain due to malignancy''; ClinicalTrials.gov #NCT01291901).
Although pain associated with cancer is a significant clinical problem with unmet medical need, 37 the potential utility of HSV-mediated gene transfer to the DRG from skin inoculation is not limited to treatment of cancer pain. The recombinant replication-defective HSV approach represents a platform technology-nerve targeting drug delivery system (NTDDS)-that can be used to deliver and express any of a number of genes in the nervous system. A related NTDDS vector, NG2, which expresses human glutamic acid decarboxylase to effect the release of the inhibitory neurotransmitter c aminobutyric acid, reduces pain-related behaviors in preclinical models of neuropathic pain from nerve injury 38 and diabetes. 39 Clinical trials of NTTDS vectors in pain have the advantage that the biological effect of the transgene product can be assessed continuously in real time. NTDDS gene transfer to the DRG to express neurotrophins locally prevents the progression of polyneuropathy in relevant preclinical models, [40] [41] [42] suggesting that the NTDDS platform may be used to treat degenerative polyneuropathies as well.
